Rising costs, unpredictable policies, and dwindling incentives are forcing Big Pharma to rethink the UK, with leading firms pausing multi-million-pound R&D projects, but why is the country losing its competitive edge?
Optimising a drug’s ability to reach diseased body parts in adequate levels while avoiding healthy body parts – its tissue exposure and selectivity – is critical to therapeutic optimisation.
Nick Morland, Tenacious Labs CEO, All-Party Parliamentary Group for CBD Products Secretariat, Jersey Cannabis Services Advisory Board Chair, writes about the UK Cannabis Industry – could this be the next Scottish Whisky?
One million homes will be given cannabis plants across Thailand, to mark the legalisation and attract foreign tourists – to be used for ‘medicinal purposes’ only.
Magnus Heunicke, Minister for Health at the Danish Ministry of Health, argues that one size doesn’t fit all when it comes to Denmark moving towards personalised medicine.
